How to manage… how to manage mantle cell lymphoma

Leukemia

Volumn 28, Issue , 2014, Pages 2117-2130

  Dreyling, M ^a   Ferrero, S ^b   Hermine, O ^c,d  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d IMAGINE INSTITUTE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CYTARABINE; MONOCLONAL ANTIBODY; RITUXIMAB;

AGED; ALGORITHM; CANCER STAGING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; WATCHFUL WAITING;

AGED; ALGORITHMS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; CYTARABINE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; WATCHFUL WAITING;

EID: 84910099125     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.171     Document Type: Article

References (137)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edn. IARC Press: Lyon, 2008, pp 233–237.
2. Gianni AM, Magni M, Martelli M, Di Nicola M, Carlo-Stella C, Pilotti S et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003; 102: 749–755.
3. Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677–2684.
4. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. JClinOncol2005; 23: 7013–7023.
5. Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687–2693.
6. Delarue R, Haioun C, Ribrag V, Brice P, Delmer A, Tilly H et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d’Etude des Lymphomes de l’Adulte. Blood 2013; 121: 48–53.
7. Hermine O, Hoster E, Walewski J, Ribrag V, Brousse N, Thieblemont C et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) increases overall survival when compared to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: final analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts) 2012; 120: 151.
8. Pott C, Hoster E, Delfau-Larue MH, Beldjord K, Böttcher S, Asnafi V et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010; 115: 3215–3223.
9. Griffiths R, Mikhael J, Gleeson M, Danese M, Dreyling M. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011; 118: 4808–4816.
10. Kluin-Nelemans HC, Hoster E, Hermine O, Walewski J, Trneny M, Geisler CH et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520–531.
11. Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 2013; 31: 1442–1449.
12. Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26–38.
13. Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996; 87: 3351–3359.
14. Hernández L, Beà S, Pinyol M, Ott G, Katzenberger T, Rosenwald A et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 2005; 65: 2199–2206.
15. Pinyol M, Bea S, Plà L, Ribrag V, Bosq J, Rosenwald A et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 2007; 109: 5422–5429.
16. Conconi A, Franceschetti S, Lobetti-Bodoni C, Stathis A, Margiotta-Casaluci G, Ramponi A et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma 2013; 54: 1908–1914.
17. Cheah CY, George A, Giné E, Chiappella A, Kluin-Nelemans HC, Jurczak W et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 2013; 24: 2119–2123.
18. Dreyling M, Thieblemont C, Gallamini A, Arcaini L, Campo E, Hermine O et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857–877.
19. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright G, Rosenwald A et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005; 106: 4315–4321.
20. Salaverria I, Royo C, Carvajal-Cuenca A, Clot G, Navarro A, Valera A et al. CCND2 rearrangements are the most frequent genetic events in cyclin D1() mantle cell lymphoma. Blood 2013; 121: 1394–1402.
21. Mozos A, Royo C, Hartmann E, De Jong D, Baró C, Valera A et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009; 94: 1555–1562.
22. Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008; 111: 2385–2387.
23. Hoster E, Klapper W, Rosenwald A, Bernd HW, Hartmann S, Loddenkemper C et al. Cell proliferation (Ki-67) as prognostic marker in mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2012; 120: 2677.
24. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558–565.
25. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al. Revised response criteria for malignant lymphoma. JclinOncol 2007; 25: 579–586.
26. Hosein PJ, Pastorini VH, Paes FM, Eber D, Chapman JR, Serafini AN et al. Utility of positron emission tomography scans in mantle cell lymphoma. Am J Hematol 2011; 86: 841–845.
27. Cohen JB, Hall NC, Ruppert AS, Jones JA, Porcu P, Baiocchi R et al. Association of pre-transplantation positron emission tomography/computed tomography and outcomeinmantlecelllymphoma.Bone Marrow Transplant 2013; 48: 1212–1217.
28. Bernard M, Tsang RW, Le LW, Hodgson DC, Sun A, Wells W et al. Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma 2013; 54: 261–267.
29. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003; 97: 586–591.
30. Velders GA, Kluin-Nelemans JC, De Boer CJ, Hermans J, Noordijk EM, Schuuring E et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996; 14: 1269–1274.
31. Geisler CH, Kolstad A, Laurell A, Räty R, Jerkeman M, Eriksson M et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive firstline immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115: 1530–1533.
32. van de Schans SA, Janssen-Heijnen ML, Nijziel MR, Steyerberg EW, van Spronsen DJ. Validation, revision and extension of the Mantle Cell Lymphoma International Prognostic Index in a population-based setting. Haematologica 2010; 95: 1503–1509.
33. Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 2011; 29: 3023–3029.
34. Hiddemann W, Unterhalt M, Herrmann R, Wöltjen HH, Kreuser ED, Trümper L et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998; 16: 1922–1930.
35. Martin P, Chadburn A, Christos P, Weil K, Furman RR, Ruan J et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27: 1209–1213.
36. Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010; 70: 1408–1418.
37. Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 2012; 72: 5307–5316.
38. Wang X, Asplund AC, Porwit A, Flygare J, Smith CI, Christensson B et al. The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival. Br J Haematol 2008; 143: 248–252.
39. Nygren L, Baumgartner Wennerholm S, Klimkowska M, Christensson B, Kimby E, Sander B. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma. Blood 2012; 119: 4215–4223.
40. Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494–502.
41. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G. A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009; 115: 4547–4553.
42. Merli F, Luminari S, Ilariucci F, Petrini M, Visco C, Ambrosetti A et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346–353.
43. Bernstein SH, Epner E, Unger JM, Leblanc M, Cebula E, Burack R et al. A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 2013; 24: 1587–1593.
44. Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012; 23: 166–171.
45. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009; 27: 6101–6108.
46. van ’t Veer MB, de Jong D, MacKenzie M, Kluin-Nelemans HC, van Oers MH, Zijlstra J et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009; 144: 524–530.
47. Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K et al. Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC. Ann Hematol 2014; 93: 233–242.
48. Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Trümper L, Hallek L et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2009; 114: 880.
49. Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984–1992.
50. Pott C, Hoster E, Beldjord K, Macintyre AE, Böttcher S, Asnafi V et al. R-CHOP/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL Younger Intergroup Trial of the European MCL Network. Blood (ASH Annual Meeting Abstracts) 2010; 116: 965.
51. Rigacci L, Fabbri A, Puccini B, Chitarrelli I, Chiappella A, Vitolo U et al. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer 2010; 116: 4573–4579.
52. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23: 3383–3389.
53. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203–1210.
54. Milpied N, Gaillard F, Moreau P, Mahé B, Souchet J, Rapp MJ et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998; 22: 645–650.
55. Peterlin P, Leux C, Gastinne T, Roland V, Mahé B, Dubruille V et al. Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients? Transplantation 2012; 94: 295–301.
56. Rubio MT, Boumendil A, Luan JJ, Canals C, Lefrère F, Attal M. Is there still a place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma?: A retrospective study from the Lymphoma Working Party of the EBMT. Blood (ASH Annual Meeting Abstracts) 2010; 116: 688.
57. Hoster E, Geisler GH, Doorduijn JK, Van der Holt B, Walewski J, Stilgenbauer S et al. Role of high-dose cytarabine and total body irradiation conditioning before autologous stem cell transplantation in mantle cell lymphoma—a comparison of Nordic MCL2, HOVON 45, and European MCL Younger Trials. Blood (ASH Annual Meeting Abstracts) 2013; 122: 3367.
58. Tam CS, Bassett R, Ledesma C, Korbling M, Alousi A, Hosing C et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144–4152.
59. Arne L, Laurell A, Jerkeman M, Grønbæk K, Elonen E, Räty R et al. Nordic MCL3 Study: zevalin combined with high-dose chemotherapy followed by autologous stem cell support as late intensification for mantle cell lymphoma (MCL) patients<66 years not in CR after induction chemoimmunotherapy: no benefit of zevalin. Blood (ASH Annual Meeting Abstracts) 2012; 120: 747.
60. Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood 2011; 118: 3419–3425.
61. Till BG, Gooley TA, Crawford N, Gopal AK, Maloney DG, Petersdorf SH et al. Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 2008; 49: 1062–1073.
62. Chang JE, Peterson C, Choi S, Eickhoff JC, Kim K, Yang DT et al. VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. Br J Haematol 2011; 155: 190–197.
63. Magni M, Di Nicola M, Carlo-Stella C, Matteucci P, Devizzi L, Tarella C et al. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant 2009; 43: 509–511.
64. Arranz R, García-Noblejas A, Grande C, Cannata-Ortiz J, Sánchez JJ, García-Marco JA et al. First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Yibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica 2013; 98: 1563–1570.
65. Khouri IF, Lee MS, Romaguera J, Mirza N, Kantarjian H, Korbling M et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999; 10: 1293–1299.
66. Kasamon YL, Jones RJ, Diehl LF, Nayer H, Borowitz MJ, Garrett-Mayer E et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005; 11: 39–46.
67. Le Gouill S, Kröger N, Dhedin N, Nagler A, Bouabdallah K, Yakoub-Agha I et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23: 2695–2703.
68. Krüger WH, Hirt C, Basara N, Niederwieser D, Behre G, Grobe N et al. Allogeneic Stem Cell Transplantation of Mantle Cell Lymphoma—Results of the Prospective Trials OSHO #060 and OSHO #074. Blood (ASH Annual Meeting Abstracts) 2011; 118: 2014.
69. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2013; 19: 625–631.
70. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013; 369: 507–516.
71. Zinzani PL, Magagnoli M, Moretti L, De Renzo A, Battista R, Zaccaria A et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol 2000; 18: 773–779.
72. Forstpointner R, Dreyling M, Repp R, Hermann S, Hänel A, Metzner B et al. The addition of rituximab to a combination of fludarabine, cyclophosphami de, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071.
73. Kenkre VP, Long WL, Eickhoff JC, Blank JH, McFarland TA, Bottner W et al. Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. Leuk Lymphoma 2011; 52: 1675–1680.
74. Ruan J, Martin P, Furman RR, Lee SM, Cheung K, Vose JM et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690–697.
75. Houot R, Le Gouill S, Ojeda Uribe M, Mounier C, Courby S, Dartigeas C et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD + C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol 2012; 23: 1555–1561.
76. Smith MR, Li H, Gordon L, Gascoyne RD, Paietta E, Forero-Torres A et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30: 3119–3126.
77. Bauwens D, Maerevoet M, Michaux L, Théate I, Hagemeijer A, Stul M et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 2005; 131: 338–340.
78. Sachanas S, Pangalis GA, Vassilakopoulos TP, Korkolopoulou P, Kontopidou FN, Athanasoulia M et al. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen. Leuk Lymphoma 2011; 52: 387–393.
79. Coleman M, Ruan G, Elstrom RL, Martin P, Leonard JP. Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology 2012; 17(Suppl 1): S90–S92.
80. Herold M, Schulze A, Niederwieser D, Franke A, Fricke HJ, Richter P et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19). J Cancer Res Clin Oncol 2006; 132: 105–112.
81. Ghielmini M, Schmitz SF, Cogliatti S, Bertoni F, Waltzer U, Fey MF et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005; 23: 705–711.
82. Zoellner A, Fritsch S, Prevalsek D, Engel N, Reibke R, Rieger CT et al. Sequential therapy combining clofarabine and HLA-haploidentical hematopoietic stem cell transplantation in the treatment of refractory and advanced lymphoma: feasibility, toxicity and early outcome. Blood (ASH Annual Meeting Abstracts) 2013; 122: 4544.
83. Weigert O, Weidmann E, Mueck R, Bentz M, von Schilling C, Rohrberg R et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma—long-term results of a multicenter observation study. Leuk Lymphoma 2009; 50: 716–722.
84. Hess G, Keller U, Atta J, Buske C, Borchmann P, Medler C et al. Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I/II trial. Blood (ASH Annual Meeting Abstracts) 2011; 118: 2697.
85. Jerkeman M, Kolstad A, Laurell A, Räty R, Grønbæk K, Pedersen LB et al. Lenalidomide, bendamustine, and rituximab as first-line therapy for patients465 years with mantle cell lymphoma: results from the phase I portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial. Blood (ASH Annual Meeting Abstracts) 2011; 118: 2700.
86. Forstpointner R, Unterhalt M, Dreyling M, Böck HP, Repp R, Wandt H et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006; 108: 4003–4008.
87. Ferrero S, Pastore A, Forstpointner R, Scholz CW, Pezzutto A, Bergmann L et al. Radioimmunotherapy in relapsed/refractory mantle cell lymphoma patients: final results of a European MCL Network Phase II Trial. Blood (ASH Annual Meeting Abstracts) 2013; 122: 4384.
88. Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20: 520–525.
89. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C et al. Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822–3829.
90. Harel S, Bachy E, Haioun C, Gyan E, Damaj G, Morineau N et al. Efficacy and safety of thalidomide in mantle cell lymphoma: results of the French ATU Program. Blood (ASH Annual Meeting Abstracts) 2010; 116: 1794.
91. Ansell SM, Tang H, Kurtin PJ, Koenig PA, Inwards DJ, Shah K et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12: 361–368.
92. Zinzani PL, Vose JM, Czuczman MS et al. Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Ann Oncol 2013; 24: 2892–2897.
93. Wang M, Fayad L, Wagner-Bartak N, Zhang L, Hagemeister F, Neelapu SS et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716–723.
94. Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol 2013; 31: 3688–3695.
95. Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 2010; 116: 2655–2664.
96. Le Gouill S, Callanan M, Macintyre E, Delfau-Larue MH, Bodet-Milin C, Meignan M et al. Clinical, metabolic and molecular responses after 4 courses of R-DHAP and after autologous stem cell transplantation for untreated mantle cell lymphoma patients included in the LyMa Trial, a Lysa Study. Blood (ASH Annual Meeting Abstracts) 2012; 120: 152.
97. Kahl BS, Li H, Smith MR, Gascoyne RD, Yang DT, Paietta E et al. Mature results from ECOG Study E1405—a phase II study of VcR-CVAD with maintenance rituximab for previously untreated mantle cell lymphoma. Blood (ASH Annual Meeting Abstracts) 2012; 120: 153.
98. van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER et al. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007; 21: 604–611.
99. Ladetto M, Magni M, Pagliano G, De Marco F, Drandi D, Ricca I et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006; 12: 1270–1276.
100. Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S et al. Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma. Ann Hematol 2013; 92: 1503–1511.
101. Andersen NS, Pedersen LB, Laurell A, Elonen E, Kolstad A, Boesen AM et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009; 27: 4365–4370.
102. Böttcher S, Ritgen M, Buske S, Gesk S, Klapper W, Hoster E et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of fourcolor flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008; 93: 551–559.
103. Kato H, Yamamoto K, Oki Y, Ine S, Taji H, Chihara D et al. Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas. Leukemia 2012; 26: 166–169.
104. van Dongen JJ, Lhermitte L, Böttcher S, Almeida J, van der Velden VH, Flores-Montero J et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012; 26: 1908–1975.
105. Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H et al. Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. Eur J Nucl Med Mol Imaging 2010; 37: 1633–1642.
106. Mato AR, Svoboda J, Feldman T, Zielonka T, Agress H, Panush D et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD. Cancer 2012; 118: 3565–3570.
107. Laurell A, Kolstad A, Jerkeman M, Räty R, Geisler CH. High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial. Leuk Lymphoma 2013; 55: 1206–1208.
108. Beà S, Valdés-Mas R, Navarro A, Salaverria I, Martín-Garcia D, Jares P et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 18250–18255.
109. Gopal A, Kahl BS, De Vos S, Wagner-Johnston ND, Schuster SJ, Blum KA et al. Mature response data from a phase 2 study Of PI3K-delta inhibitor idelalisib in patients with double (rituximab and alkylating agent)-refractory indolent B-cell non-Hodgkin lymphoma (iNHL). Blood (ASH Annual Meeting Abstracts) 2013; 122: 85.
110. Kahl BS, Byrd JC, Flinn IW, Wagner-Johnston N, Spurgeon S, Benson DM et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase p110{delta}, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts) 2010; 116: 1777.
111. Magni M, Di Nicola M, Carlo-Stella C, Devizzi L, Guidetti A, Matteucci P et al. Safety, tolerability and activity of ofatumumab, bendamustine and dexamethasone combination as first-line treatment of mantle-cell lymphoma in the elderly: a multicenter study. Blood (ASH Annual Meeting Abstracts) 2011; 118: 1647.
112. Vose JM, Loberiza FR, Bociek G, Bierman P, James O. Armitage. Phase I/II trial of ofatumumab/lenalidamide for patients with relasped/refractory B-cell nonHodgkin lymphoma: high response rate in indolent lymphoma. Blood (ASH Annual Meeting Abstracts) 2012; 120: 3692.
113. Morschhauser FA, Cartron G, Thieblemont C, Solal-Céligny P, Haioun C, Bouabdallah R et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol 2013; 31: 2912–2919.
114. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974–977.
115. Viardot A, Goebeler M, Scheele JS, Zugmaier G, Noppeney R, Knop S et al. Treatment of patients with non-Hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): double-step dose increase to continuous infusion of 60 μg/m2/d is tolerable and highly effective. Blood (ASH Annual Meeting Abstracts) 2010; 116: 2880.
116. Palanca-Wessels MC, Salles GA, Czuczman MS, Assouline SE, Flinn IW, Sehn LS et al. Final results of a phase I study of the anti-CD79b antibody-drug conjugate DCDS4501A in relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2013; 122: 4400.
117. Lin TS, Blum KA, Fischer DB, Mitchell SM, Ruppert AS, Porcu P et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010; 28: 418–423.
118. Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 2011; 17: 3388–3397.
119. Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119: 4597–4607.
120. Evens AM, Vose JM, Harb W, Gordon LI, Langdon R, Grant B et al. A phase II multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 2012; 120: 55.
121. Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG et al. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/ refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood (ASH Annual Meeting Abstracts) 2013; 122: 1789.
122. Herold M, Haas A et al. Immunochemotherapy (R-MCP) in advanced mantele cell lymphoma is not superior to chemotherapy (MCP) alone-50 months update of the OSHO phase III study (OSHO#39). Annals Oncol 2008; 19: abstract 12.
123. Gressin R, Caulet-Maugendre S, Deconinck E, Tournilhac O, Gyan E, Moles MP et al. Evaluation of the (R)VAD + C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group. Haematologica 2010; 95: 1350–1357.
124. Rummel M, Kaiser U, Balser et al. Bendamustine plus rituximab versus fludarabine plus rituximan in patients with relapsed follicular, indolent and mantle cell lymphomas-final results of the randomized phase III study NHL 2-2003 on behalf of the STIL. Blood 2010; 116: 856.
125. Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007; 18: 370–375.
126. Rodríguez J, Gutierrez A, Palacios A, Navarrete M, Blancas I, Alarcón Jet al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007; 48: 2172–2178.
127. Garbo LE, Flynn PJ, MacRae MA, Rauch MA, Wang Y, Kolibaba KS et al. Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma. Invest New Drugs 2009; 27: 476–481.
128. Baiocchi RA, Alinari L, Lustberg ME, Lin TS, Porcu P, Li X et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011; 117: 2442–2451.
129. Lamm W, Kaufmann H, Raderer M, Hoffmann M, Chott A, Zielinski C et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011; 96: 1008–1014.
130. Gerecitano J, Portlock C, Hamlin P, Moskowitz CH, Noy A, Straus D et al. Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res 2011; 17: 2493–2501.
131. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807–2812.
132. Kouroukis CT, Fernandez LA, Crump M, Gascoyne RD, Chua NS, Buckstein R et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 2011; 52: 394–399.
133. Witzig TE, Geyer SM, Ghobrial I, Inwards DJ, Fonseca R, Kurtin P et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23: 5347–5356.
134. Ansell SM, Inwards DJ, Rowland Jr KM, Flynn PJ, Morton RF, Moore Jr DF et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113: 508–514.
135. Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F et al. and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97: 1085–1091.
136. Zaja F, De Luca S, Vitolo U, Orsucci L, Levis A, Salvi F et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416–422.
137. Wang M, Oki Y, Pro B, Romaguera JE, Rodriguez MA, Samaniego F et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213–5218.